Ad Banner

Coronavirus Latest Update in China. Chinese Corona Virus Updates

Tsinghua and Shenzhen Third Hospital isolate neocrown virus antibodies, will promote clinical application

At present, Zhang Linqi and Zhang Zheng's team are collaborating with Professor Wang Xinquan of the School of Life Sciences, Tsinghua University to conduct systematic structural and functional research on these antibodies, select the optimal antibodies, and promote large-scale production, preclinical animal research and subsequent clinical application development.

Beijing News (Reporter Fan Shuo) Recently, Zhang Linqi's team at the Tsinghua University School of Medicine and Zhang Zheng's research team at the Shenzhen Third People's Hospital successfully isolated more than 200 anti-neoviruses from blood B lymphocytes in patients with neo-coronary pneumonia. Monoclonal antibodies and their encoding genes. The results have been published on the preprinted platform BioRxiv. In an interview with the Beijing News on March 29, the above team stated that they are currently collaborating with Professor Wang Xinquan of the School of Life Sciences at Tsinghua University to select the best antibodies to promote large-scale production, preclinical animal research and follow-up clinical applications, Development.

Monoclonal antibodies or new crown specific drugs

Zhang Linqi told reporters that this monoclonal antibody only has a strong recognition effect on the new crown virus, "this antibody belongs to the specific drug against the new crown virus."
The paper published by Zhang Linqi and Zhang Zheng's research team on BioRxiv showed that the invasion of human cedar virus by humans depends on the binding between the virus S protein receptor binding domain (RBD) and the target of the cell angiotensin converting enzyme 2 (ACE2) receptor. 

The above-mentioned team isolated 206 monoclonal antibodies against neocoronavirus, two of which showed strong anti-neurovirus, which can convert neocoronavirus S protein receptor binding domain (RBD) and angiotensin in human cells. Enzyme 2 (ACE2) binding decreased by 99.2% and 98.5%.

On February 8th, the National Health and Medical Commission's "Diagnosis and Treatment of New Coronavirus Pneumonia" (the fifth revised version of the trial) mentioned that the treatment plan for severe and critical cases can be treated with recovery plasma. Among them, antibodies present in the plasma during recovery of patients with new coronary pneumonia are the key to help the treatment of critically ill patients.

According to Zhang Zheng, there are two main methods of plasma treatment at present, one is to directly use the recovery period plasma, and the other is to extract the immunoglobulin from the recovery period plasma. Although it has been clinically proven to have a certain effect on new coronary pneumonia, in the traditional "plasma therapy", there are problems such as trans blood type, low efficiency, difficult to save plasma, and limited sources. The immunoglobulin extracted from the plasma during recovery is actually a polyclonal antibody, and there is also a problem of low efficiency in clinical treatment.

"The antibodies in the recovery plasma are actually a mixture of tens of thousands of antibodies." Zhang Linqi said that the team's method of extracting monoclonal antibodies was actually selecting high efficiency from tens of millions of different antibody mixtures. A key antibody that blocks the virus from entering the cell, breaking the virus's replication chain.

A lot of work is still needed for clinical application

A lot of work is still needed from the currently isolated antibodies to the actual application to patients. At present, Zhang Linqi and Zhang Zheng's team are collaborating with Professor Wang Xinquan of the School of Life Sciences, Tsinghua University to conduct systematic structural and functional research on these antibodies, select the optimal antibodies, and promote large-scale production, preclinical animal research, and subsequent clinical application development.

"The whole process is as short as possible." Zhang Linqi revealed that it usually takes 9 months to a year and a half from the routine antibody development to the clinical trial. "The country has actually established a good service platform, and we also I am confident that I will be able to complete a large number of production and process development and animal safety assessments in about six months, and then report to the drug review center for a Phase I clinical trial. "

New study: pangolin carries coronavirus similar to new coronavirus

Researchers from Shantou University-Hong Kong University Joint Institute of Virology and Guangxi Medical University have reported in the British journal Nature that they have smuggled pangolin samples Coronaviruses similar to neocoronaviruses were found. 
However, this similarity is not enough to indicate that pangolin is the intermediate host that caused the current outbreak.

Researchers obtained multiple smuggled pangolin samples intercepted in Guangxi, Guangdong, China in recent years, and analyzed the samples by high-throughput RNA (ribonucleic acid) analysis. They found that the pangolins carry coronaviruses that are similar to the new coronavirus genome sequences Degrees range from 85.5% to 92.4%.

The analysis shows that on the coronavirus evolution tree, the coronaviruses and neocoronaviruses carried by these pangolins are in the "new coronavirus-related evolutionary branch". The pangolins that carry coronavirus belong to two subtypes of this branch, one of which The Knappin receptor binding domain is 97.4% similar to Neocoronavirus.

The receptor-binding domain of spike protein acts like a "hook" that can hook into the host cell and plays a key role in the process of virus invasion.

To date, the closest known strain to the new coronavirus is the coronavirus found by bats from researchers such as the Wuhan Institute of Virology of the Chinese Academy of Sciences. It has 96% identity with the new coronavirus genome and a similarity in the receptor binding domain of 89.2%.

Researchers said pangolins are the only mammals known to have been infected with a coronavirus associated with a coronavirus to date, except bats, and may be a long-term host for such viruses.

Researchers point out that the latest findings are not enough to indicate that pangolin is the intermediate host that caused the current outbreak, but it should be considered as a possible host of the new crown virus. Strictly banning pangolin trading in the market will reduce the risk of future virus transmission to humans.

Previously, a team from Lingnan Modern Agricultural Science and Technology Guangdong Laboratory and South China Agricultural University published a preprinted paper saying that their pangolin spliced ​​from the metagenome carried a coronavirus sequence that was approximately 90% similar to the new coronavirus genome sequence, indicating that pangolins Probably an intermediate host of the new crown virus. This paper has not been peer reviewed.

China takes the lead in launching clinical trials against respiratory syncytial virus

With the advent of cold winter weather, the number of cold patients has gradually increased. The impact of the flu epidemic last year has made many people gradually understand and value "cold" gradually, but it needs to be clear to everyone that "cold" is not all "Influenza", respiratory syncytial virus (RSV) is also one of the main culprits. After most adults are infected with this virus, the clinical symptoms are similar to those of upper respiratory tract infections caused by general influenza, and runny nose and cough will appear.

Academician Wang Chen speaks

At the launch of the Phase II clinical trial of the new anti-respiratory syncytial virus AK0529 in China on November 21, Prof. Wang Chen, member of the Chinese Academy of Engineering, director of the National Research Center for Respiratory Diseases, and director of the Respiratory Center of China-Japan Friendship Hospital, took charge of this project. The national leader said that this is the first clinical study in China and the world to observe the efficacy in adult patients with natural infection with respiratory syncytial virus, and it is expected to fill a gap in the field of respiratory virus treatment at home and abroad.

It is understood that as there is no effective medicine for the treatment of respiratory syncytial virus worldwide, it has brought a huge burden on the health care systems of countries around the world. Most children are infected with respiratory syncytial virus within two years after birth. In preterm infants, young children, immunocompromised adults, and the elderly, the symptoms of the infection are more severe. In these high-risk groups, the "common cold" can evolve into lower respiratory infections, pneumonia, bronchiolitis, and other serious respiratory problems, which can be fatal in a few cases.

Respiratory syncytial virus is highly contagious. It can be spread through droplets from coughing or sneezing, and because it can survive on the surface of objects, people are easily infected when they come into contact with these contaminated things. Outbreaks occur only in spring and autumn and winter in temperate regions, and are endemic throughout the year in tropical, subtropical, and cold regions. In adults, especially those with low immunity, and the elderly, RSV infection usually causes symptoms such as nasal congestion, runny nose, cough, fever, sore throat, and headache; in severe cases, the virus spreads to the lower respiratory tract, causing pneumonia and bronchitis, and fever , Headache, sore throat, severe cough, shortness of breath or severe dyspnea, ventilator-assisted ventilation is needed, and skin and lips may become blue due to hypoxia.

According to WHO data, nearly 30 million elderly patients with respiratory syncytial virus infection worldwide each year, and at least 2 million are critically ill patients. Experts from the Chinese University of Hong Kong School of Medicine analyzed the situation of nearly 20,000 inpatients diagnosed with respiratory virus infection in the past 15 years and found that respiratory syncytial virus and influenza A virus were listed as the two main killers of children and the elderly. Respiratory syncytial virus accounts for 20% of the deaths. Respiratory syncytial virus infection can last up to about 20 days. Many patients mistakenly believe that influenza is often untreated or used anti-influenza virus drugs. When 7 days have passed, Not getting better and turning to anxiety, or even blindly taking medicine, further worsened the condition.

Professor Cao Bin, Executive Deputy Director of the Respiratory Center of China-Japan Friendship Hospital, shared the progress of diagnosis and treatment of respiratory syncytial virus infectious diseases at the meeting. He noted in the report that the results of a recent epidemiological survey show that approximately 487,247 people in the RSV epidemic season in the UK alone require medical treatment, 17,799 hospitalizations, and 8,482 deaths; Patients accounted for approximately 36% of these medical treatments, 79% of hospitalizations, and 93% of deaths. Results from Asia are similar, with data from a South Korean study showing that all-day mortality from respiratory syncytial virus infection in patients over 18 years is higher than influenza (18.4% vs. 6.7%) and seasonal influenza.

 Compared to the group, the risk of death from RSV infection was significantly higher. "China currently has more than 240 million people over the age of 60, all of whom are at high risk for respiratory syncytial virus infection. The burden on families and society is huge. The results of the AK0529 phase II clinical trial in China's adults are expected to fill the virus treatment in China and the world. 

CITIC Securities: vaccines, mRNA, and adenovirus vectors will be the antidote to the new crown virus epidemic

The domestic epidemic situation is getting better, but the overseas epidemic situation has become more serious recently. The number of confirmed cases in many countries has surged, which has also increased the risk of imported epidemics in China. How to overcome COVID-19 is still the focus of the whole society. As Academician Zhong Nanshan said, on the one hand, it is urgent to develop a special treatment for COVID-19. On the other hand, COVID-19 is not a lifelong immunity for infection. Developing a vaccine or a more effective solution is the most powerful technology weapon to end the epidemic. .

Vaccines are the root cause of COVID-19 pneumonia and have attracted much attention from investors.

As of the close of March 19 local time, related companies Inovio Pharmaceuticals, Moderna and BioNTech in the field of nucleic acid vaccines have recorded good gains after the announcement, rising 47.84% / 52.07% / 59.75% respectively, highly sought after by investors; domestic COVID -19 vaccine development is synchronized with the world. At the joint defense and joint control conference of the State Council on March 17, it was mentioned that China is carrying out the emergency development of the COVID-19 vaccine according to five technical routes. Among them, the scientific research team led by Academician Chen Wei of the Academy of Military Sciences has made the fastest progress, and completed the registration of the Phase I clinical trial on March 17.
The preliminary results are expected to be released in 6 months. Combining innovative second- and third-generation vaccine technologies and relaxation of approval policies, we judge that the development of COVID-19 vaccine is expected to accelerate.

mRNA: A promising new treatment, the vaccine has completed the first subject injection (FPI)

mRNA therapy has multiple advantages such as strong immune activity and short R & D cycle. It presents a three-legged pattern (Moderna, BioNTech and CureVac). Currently, both Moderna and BioNTech have been listed on NASDAQ. At the same time, traditional pharmaceutical companies have also laid out mRNA race tracks through cooperation. From the perspective of research and development progress, Moderna has made the fastest progress. The clinical phase I trial of mRNA-1273 against COVID-19 vaccine was launched on March 16 and is the world's first clinical trial against COVID-19 vaccine. BioNTech is close behind, and is expected to enter clinical trials in late April. Fosun Pharma will be responsible for commercialization in China.

Adenoviral vectors: There are precedents for commercial success.

Recombinant virus vector vaccine refers to a virus that uses a virus as a vector to insert a foreign protective antigen gene into the viral genome and transfect cells to obtain a recombinant virus. After immunizing the body, the corresponding protein of interest is expressed, thereby inducing an immune response. Carrier-like vaccine. At present, a variety of viral vectors including pox virus, adenovirus, herpes virus (HSV), etc. have been used for vaccine research. Among them, adenoviruses have a wide range of hosts, are prone to produce high titer virus particles, and can accommodate large fragments of foreign genes. , Has a good application prospect in preventive vaccine vectors. COVID-19 based on the adenovirus platform is expected to become a research and development hotspot at home and abroad. The Ad5-nCoV project carried out by Academician Chen Wei of the Academy of Military Sciences is worth looking forward to.

Risk factors

Risks of uncertain R & D progress, risk of drug price reduction, and risk of individual stock performance falling short of expectations.

Investment Strategy

At present, mRNA and adenoviral vector vaccines are the shortest R & D cycle and the best commercialization technology path. Domestic listed companies mostly adopt cooperative forms to jointly advance. It is recommended to focus on Fosun Pharma, which has reached a strategic cooperation with BioNTech. Kangtai Biological, Zhifei Biological, etc.

Chinese Corona virus

Advise DPP authorities and Su Zhenchang to stop spreading political virus immediately

Zhu Fenglian, a spokesman for the State Council Taiwan Affairs Office, said on the 24th that Su Zhenchang once again shamelessly spread "Su-style lies", blatantly rumors that the mainland "concealed the epidemic." This act of inciting discrimination and hatred by making lies, once again exposed his vicious nature to the world.

Zhu Fenglian said that in the past two months or so, the people of the mainland have united as one and worked hard to fight the epidemic. The achievements they have achieved are universally recognized and they have won precious time for epidemic prevention worldwide. 

At the same time, they have always taken a highly responsible attitude towards the lives and health of the people of Taiwan. They have notified the relevant Taiwan authorities of the epidemic from the beginning, including the information on the mainland’s and WHO ’s sharing of the New Coronavirus gene sequence and access to related gene sequence information. 
As of March end, it has notified 101 times. The DPP authorities have never dared to tell these truths to the people of Taiwan.

Zhu Fenglian pointed out that "Su-style lies" have been repeatedly face-scrapped by facts. The epidemic situation in Taiwan is intensifying. The DPP authorities and Su Zhenchang are advised to immediately stop spreading the political virus. It is both shameful and disgusting to continue to “ignite” the epidemic to raise cross-strait confrontation and worsen the atmosphere of cross-strait relations.

New research finds that Pleurotus ostreatus has antiviral and anti-inflammatory effects on new crown virus

For the latest news, the scientific research team of Academician Zhong Nanshan entitled "Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2)" has been accepted by the journal Pharmacological Research.

The authors of the paper include Zhong Nanshan, director of the State Key Laboratory of Respiratory Diseases, Guangzhou Medical University, and researcher Yang Zifeng.

"Pharmacological Research" is a well-known pharmacological journal under the Elsevier Publishing Collective and a classic pharmacological journal. This journal mainly publishes cutting-edge articles in the field of biomedical science and enjoys a high reputation in the pharmaceutical industry.

The paper mentions that as a traditional Chinese medicine prescription, Lianhua Qingwen has broad-spectrum antiviral and immunoregulatory effects on a range of influenza viruses.

The study found that Pleurotus ostreatus can significantly inhibit the replication of Neocoronavirus in cells, and the expression of virus particles in the cells was significantly reduced after treatment of Pediatricus Plasmodium. IL-6, MCP-1 and IP-10 genes are over-expressed in a dose-dependent manner.

This study confirms that even flower clear blast can play an anti-neovirus activity by inhibiting virus replication, causing changes in the shape of virus particles and suppressing the expression of inflammatory factors in host cells. This shows that even flower clear blast can resist virus attack and is expected to become a new crown for prevention New strategies for pneumonia.

It is understood that Lianhua Qingwen is a prescription formulated under the guidance of the theory of collateral disease and the method of "clearing and detoxifying, demonstrating lungs and reducing fever", and is recommended for colds, flu, and avian flu by 20 national guidelines, consensus, and treatment plans. , Middle East Respiratory Syndrome (MERS) and other respiratory diseases. At present, Lianhua Qingwen Capsule (granule) has been included in the national version of "Pneumonitis Diagnosis and Treatment Program for New Coronavirus Infection".

 Traditional Chinese medicine for new coronary pneumonia, the total effective rate is more than 90%

At 16:00 on March 23, the State Council Information Office held a press conference in Wuhan, Hubei to introduce the important role of Chinese medicine in the prevention and treatment of new crown pneumonia and effective drugs.

Yu Yanhong, member of the Central Steering Group, member of the Party Committee of the Health and Health Committee, and secretary of the Party Group of the Chinese Medicine Bureau, introduced that the State Administration of Traditional Chinese Medicine has conducted simultaneous observation of the clinical efficacy of proprietary Chinese medicines and prescriptions that have been included in the fifth, sixth, and seventh edition of the treatment plan "Jinhua Qinggan Granules, Lianhua Qingwen Capsules, Xuebijing Injection and Qingfei Paidu Decoction, Huashi Baidu Decoction, Xuanfei Baidu Decoction, etc." have been selected.

According to statistics, 74,187 of the confirmed cases nationwide were treated with Chinese medicine, accounting for 91.5% of the total; 61,449 patients in Hubei were treated with Chinese medicine, accounting for 90.6%. The clinical efficacy observations show that the total effective rate of traditional Chinese medicine treatment is more than 90%, which effectively relieves the symptoms of patients, reduces the development of light and ordinary patients to heavy, improves the cure rate, reduces the mortality rate, and promotes the physical recovery of the recovery period. .

Yu Yanhong said that in the absence of specific medicines and vaccines in the early stage of the new crown pneumonia epidemic, the law and experience of traditional Chinese medicine in treating viral infectious diseases were summarized, and ancient classics were deeply explored. Combined with clinical practice, traditional Chinese medicine and traditional Chinese and western medicine were formed. Combined with the diagnosis and treatment plan for the treatment of new coronary pneumonia, it has become an important feature and advantage of the Chinese plan, and a batch of effective prescriptions represented by "three drugs and three parties" were screened. This practice has fully proved once again that the precious wealth left by the old ancestors of traditional Chinese medicine has been tried and tested for a long time, and it is worth cherishing. It is still easy to use, effective, and economically feasible.

In the epidemic, a large number of Chinese medicines were approved

According to China Net News, on March 18, Huashi Baidu Granule was approved by the State Drug Administration for clinical trials, which is also the first Chinese medicine clinical approval for the treatment of new coronary pneumonia in China.

Huashi Baidu Granules were developed by the first batch of National Aid-resistant Anti-epidemic Traditional Chinese Medical Team (China Academy of Chinese Medical Sciences) led by Huang Luqi, a member of the Chinese Academy of Engineering and the president of the Chinese Academy of Chinese Medical Sciences.

Huashi Badu Fang is the first batch of national medical teams in the country to gradually form the process of "salvation while summing up" during the actual treatment of Jinyintan Hospital and the Dongfanghu Fangcai Hospital. It can fight the virus, eliminate inflammation, improve immunity, and played an active role in the treatment of Wuhan New Crown patients.

Academician Zhong Nanshan also previously stated at the outbreak prevention and control conference held in Guangdong: "I attach great importance to the role of traditional Chinese medicine in the laboratory on the new crown virus. Once there is evidence, traditional Chinese medicine can be used with confidence, especially in the early and middle stages."

On the one hand, the state recommends the use of effective prescriptions for new coronary pneumonia traditional Chinese medicine; on the other hand, a batch of traditional Chinese medicine preparations for new coronary pneumonia have also been approved through emergency review.

According to, as of the end of February, 21 Chinese medicine preparations have been approved by the provincial drug regulatory bureaus to prevent and control pneumonia outbreaks of new coronavirus infections.
As Academician Zhang Boli said at the State Council press conference on March 23, "I don't panic if you have medicine in your hand. Every time after a major epidemic, a good medicine will come out, so there is a saying," The epidemic "Good medicine," after a major epidemic, a batch of good medicine will be issued. "

In response to the new crown pneumonia epidemic, we have no specific medicines or vaccines, but in the process of epidemic prevention, we can actively explore the path of integrating traditional Chinese and western medicine for different patients, which is another improvement of traditional Chinese medicine.

Special statement: The above contents (including pictures or videos are also included) are uploaded and published from users of the media platform "NetEase account", this platform only provides information storage services.

Tracing the virus all night long: The quality of the epidemiological investigation is related to whether the source of infection and potential infected persons can be identified in time, and the spread of the epidemic can be controlled. Yuan Jun, chief physician of the Guangzhou Municipal Center for Disease Control and Prevention, as the team leader of the emergency treatment team for the prevention and control of new crown pneumonia in the city, led the team members of the "detective" for disease control to break the cocoons and solve the "mysteries" of virus transmission. 

Aid Xinjiang returns to the front line in half a month

In early January, Yuan Jun ended three years of aid to Xinjiang and returned to Guangzhou for a rest. As the situation of prevention and control of the new crown pneumonia epidemic in Guangzhou gradually became tense, he twice asked the unit for approval after the war and officially returned to work. On the third day of this year, Yuan Jun was appointed as the leader of the emergency treatment team for the new crown pneumonia prevention and control of the Municipal Center for Disease Control and Prevention.

Yuan Jun said that he studied preventive medicine at the university. SARS, H1N1 influenza, H7N9 bird flu and other major public health incidents were on the front line. In 2005, he went to Beijing to participate in the two-year China Field Control Epidemiology Training Program of the Chinese Centers for Disease Control and Prevention (Fifth Phase). Most of the 12 graduates in the current period were in the frontline during this war. "This epidemic is the time when our values ​​are best reflected, and also when the country and the people need them most. As a public health doctor and a party member, I must rush to the front line, otherwise, my life will Sorry. "

The epidemiological investigation is one of the core tasks of the CDC in the prevention and control of infectious diseases, and it is also the main work of the emergency treatment team of the Municipal Center for Disease Control and Prevention led by Jun Jun. 

Where does the virus come from? Who else might it spread to?
"Only by identifying the source of infection and close contacts of the cases and isolating them in time, can the immune system be prevented from spreading further.

Tracing the source of infection with a team of 200 people

In order to reshape the chain of transmission, Yuan Jun and his colleagues went to the patient's home, to the hospital, to the various places that the patient had visited 14 days before the onset of the disease, to find the patient, to see the doctor, to find everything that could be found in these 14 days. People who have been in contact, observe whether the on-site environment is likely to cause conditions for transmission, and understand their whereabouts.

The quality of the epidemiological investigation determines whether the prevention and control work is accurate and whether the source of infection and the route of transmission can be "early grasped". Since the outbreak of the "epidemic", Yuan Jun, as the leader of the emergency response team, has established a joint urban epidemiological investigation team of more than 200 people. The quality of the epidemiological investigation report has thus been greatly improved in a short period of time. The ratio of each case to the close contacts found has increased from 1: 2 in January to the current 1:13, ensuring the prevention and control effect.

Although the scope of this work was in Guangzhou, Yuan Jun was almost absent from home every day: In order to gather time for the clues of epidemiological investigations, he and his colleagues often dispatched field investigations throughout the night. Without entering. " Even if I go home occasionally at night, it ’s mostly late at night. I ’m going to change clothes and my family is asleep. Occasionally, I go home early because I ’m worried about the risks of going out of the hospital and other places. Able to avoid it.

"The new crown virus is more cunning than the SARS virus, because the infected person may not have a fever or asymptoms, which adds a lot of difficulty to us in terms of prevention and control. However, even if it is difficult, we must try our best to do it as soon as possible. Keep it under control, suppress the epidemic situation, delay the spread of the process, and find time for effective research and development of vaccines for clinical research and development, "said Jun Jun." As long as the epidemic can be controlled as early as possible, all the suffering is worth it. "
According to the authoritative statement issued by the Jiangsu Provincial Health and Health Commission on March 20: at 04:00 on March last day, there were no new confirmed cases of new coronavirus pneumonia in Jiangsu.

As of 24:00 on March 19, Jiangsu Province had reported a total of 631 confirmed cases of new coronavirus pneumonia. Among them, there were:
  1.   93 cases in Nanjing
  2.  55 cases in Wuxi
  3.  79 cases in Xuzhou
  4.  51 cases in Changzhou
  5.  87 cases in Suzhou
  6.  40 cases in Nantong
  7.  48 cases in Lianyungang
  8.  66 cases in Huai'an
  9.  27 cases in Yancheng
  10.  23 in Yangzhou
There were:
  •  12 cases in Zhenjiang
  •  37 cases in Taizhou
  •  13 cases in Suqian
A total of 631 discharged patients.

At present, Jiangsu Province has tracked 12,657 close contacts, 12,644 people have been released from medical observation, and 13 people are still receiving medical observation.
Coronavirus Updates LIVE
Experts remind: Although the cases confirmed in the hospital are "cleared", it does not mean "zero risk". At present, the situation of overseas epidemics is very serious. We must be cautious and prevent importation. We must not relax our vigilance against epidemics and reduce the requirements for prevention and control. We must ensure that work is not slack and epidemics do not rebound.

The public must continue to be aware of precautions and develop good hygiene habits, such as wearing a mask, washing hands frequently, paying attention to cough etiquette, and ventilating and cleaning the room daily to minimize aggregation and effectively reduce the risk of infection.

Appointment consultations have been implemented in hospitals above the provincial level. In order to reduce the staff gathering and shorten the waiting time in the hospital, please register in advance through a variety of channels, such as online registration, mobile APP appointments, phone appointments, SMS appointments, clinic appointments, on-site self-service appointment appointments, etc.

Post a Comment